ANSWERS OF DR. BROTZU TO QUESTIONS

The answer to your question is complex and it is almost impossible to answer all individually. I must clarify the mechanism of action of the lotion and on what principles it is based.
The alopecia (androgenetic alopecia totalis and) have the basis of a blood flow deficit at the level of capillaries that reach the hair follicles and carry oxygen and all that it is necessary for their metabolism and growth of the hairs ..

The capillaries are composed of a layer of endothelial cells that separate the tissues from the blood flow. The endothelial cells are affected by many stimuli and certain stimuli they reduce the flow in the capillaries and block their reproduction by reducing the microcirculation.
Logically stimuli can be very different between them in various types of alopecia but all act on the microcirculation supplying the called hair bulbs.
I am attaching the capillary pattern

The cell reproduced in the foreground is called pericyte and is the one that regulates blood flow in the capillaries . Minoxidil acts on it which increases the flow in the capillary but this drug does not act on endothelial cells that were affected in many stimuli such as infectious, hormonal disorders ect.
The Prostaglandin E1 (PGE1) that acts both on pericytes on endothelial cells causing their vasodilation and stimulating reproduction of the latter.
About six years ago we observed that the cationic liposomes carrying PGE1 were able to reduce the androgenic alopecia phenomena. (For completely unrelated reasons not made any research).

About 4 years ago we developed a lotion containing cationic liposomes carrying PGE 1, S-equol and Carnitine and began to experiment on people with androgenetic alopecia and then was tested on a child with alopecia areata. The results were excellent and surprising
PGE1 improved microcirculation, the s-equol blocked the 5-α- reductase preventing testosterone from turning the dihydrotestosterone and carnitine enters the beta-oxidation of lipid chains facilitating metabolism.

Read the Full Interview